The Food and Drug Administration approved Glenmark Pharamceuticals' potassium chloride tablets.
The tablets, used to treat a potassium deficiency, are a generic version of K Dur tablets produced by Merck Sharp & Dohm, a subsidiary of Kenilworth, N.J.-based Merck.
The K Dur tablets reported annual sales of $283 million for the 12-month period ending May 2016, according to IMS Health sales data.
India-based Glenmark Pharmaceuticals currently has 117 products authorized for distribution in the U.S. and 61 products pending approval from the FDA.
More articles on the drug market:
Patients in Texas and Florida gain easier access to opioid-overdose antidote naloxone
Eli Lily exceeds 2Q expectations thanks to new drug sales
Sen. Bernie Sanders' DNC speech tackles high prescription drug costs: 4 things to know